Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

By P. Robbins, R. Morgan, S. Feldman, Jie Yang, R. Sherry, M. Dudley, J. Wunderlich, Azam Nahvi, L. Helman, C. Mackall and 11 more. Journal of Clinical Oncology, 2011

1,605 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

IL-2: The First Effective Immunotherapy for Human Cancer (2014, background): “Shortly thereafter it was shown that transduction of normal lymphocytes with genes encoding TCRs against the cancer testes Ag, NY-ESO-1, could mediate tumor regression in patients with synovial cell sarcomas as well as melanomas (78).”
Gene therapy clinical trials worldwide to 2017: An update (2018, background): “Generally, clinical responses were highly variable but, importantly, a small proportion of patients were in remission post‐treatment.(16,17) Chimeric antigen receptors (CARs) represent another autologous cell‐based therapy targeting tumour‐associated cell‐surface antigens that had entered the clinic”
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. (2013, methodology): “On protocol, a dose of cyclophosphamide 60 mg/kg per day was administered for 2 days starting 4 days prior to the cell infusion since this had previously been shown to potentiate the effects of the infused engineered T cells.(3) Thus, 5.”
Adoptive immunotherapy for cancer: harnessing the T cell response (2012, neutral): “Gen mühendisliği bu tedaviye duyarlı tümör histolojilerinin çeşitliliğini büyük ölçüde arttırabilir; yeni literatürdeki birkaç örneği vermek gerekirse, bu çeşitlilik şimdilerde nörüblastom (77), sinovial hücre sarkomu (6), lösemi ve lenfoma (3, 5, 7) içermektedir.”